Engineering of a disulfide loop instead of a Zn binding loop restores the anti-proliferative, anti-angiogenic and anti-tumor activities of the N-terminal fragment of endostatin: Mechanistic and therapeutic insights
- 1 September 2015
- journal article
- Published by Elsevier in Vascular Pharmacology
- Vol. 72, 73-82
Abstract
No abstract availableKeywords
Funding Information
- Shefa neuroscience research center (90635)
This publication has 45 references indexed in Scilit:
- Angiogenesis—a new target for future therapyVascular Pharmacology, 2006
- Antiangiogenesis in cancer therapy—endostatin and its mechanisms of actionExperimental Cell Research, 2006
- A 27-Amino-Acid Synthetic Peptide Corresponding to the NH2-Terminal Zinc-Binding Domain of Endostatin Is Responsible for Its Antitumor ActivityCancer Research, 2005
- The Minimal Active Domain of Endostatin Is a Heparin-Binding Motif that Mediates Inhibition of Tumor VascularizationCancer Research, 2004
- An Endostatin-derived Peptide Interacts with Integrins and Regulates Actin Cytoskeleton and Migration of Endothelial CellsJournal of Biological Chemistry, 2004
- Studies on the Structure−Activity Relationship of Endostatin: Synthesis of Human Endostatin Peptides Exhibiting Potent Antiangiogenic ActivitiesJournal of Medicinal Chemistry, 2003
- Variable zinc coordination in endostatinJournal of Molecular Biology, 2000
- Zinc-dependent dimers observed in crystals of human endostatinProceedings of the National Academy of Sciences, 1998
- Crystal structure of the angiogenesis inhibitor endostatin at 1.5 Å resolutionThe EMBO Journal, 1998
- Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor GrowthCell, 1997